002399.SZ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 08:33):

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...

Stats
Dzisiejszy wolumen	12.64M
Średni wolumen	6.23M
Kapitalizacja rynkowa	13.11B
EPS	CNY0 ( 2024-04-28 )
Następna data zysków	( CNY0 ) 2024-05-22
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-22.36
ATR14	CNY0.0160 (0.15%)

Wolumen Korelacja

Długi: 0.19 (neutral)

Krótki: -0.14 (neutral)

Signal:(53.28) Neutral

Shenzhen Hepalink Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shenzhen Hepalink Korelacja - Waluta/Towar

0.76
( moderate )

0.80
( moderate )

0.00
( neutral )

-0.29
( neutral )

-0.73
( moderate negative )

Shenzhen Hepalink Finanse

Annual	2023
Przychody:	CNY5.42B
Zysk brutto:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2023
Przychody:	CNY5.42B
Zysk brutto:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2022
Przychody:	CNY7.16B
Zysk brutto:	CNY2.33B (32.61 %)
EPS:	CNY0.500

FY	2021
Przychody:	CNY6.37B
Zysk brutto:	CNY2.03B (31.94 %)
EPS:	CNY0.164

Financial Reports:

No articles found.

Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.